We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Recardio

News List

MHRA to consult on potential for no-deal Brexit pharmafile
November 20, 2018
The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation on how its legislation and regulatory processes would be impacted by a no-deal Brexit.
Concerns over Brexit cause Recardio to cease clinical trials in the UK pharmaceutical
November 19, 2018
California-based clinical stage pharmaceutical company Recardio has halted its UK activities due to concerns over Brexit and how it will impact the approval of medicines.
Recardio halts UK heart trial on Brexit uncertainty pharmatimes
October 11, 2018
Medical research group Recardio has reportedly halted a trial of an experimental heart drug because of uncertainties surrounding the UK’s departure from the European Union.